Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lupin Pharmaceuticals has received final approval for its abbreviated new drug application for divalproex sodium delayed-release tablets, 125mg, 250mg and 500mg from the FDA. Commercial shipments of the product have already commenced.
Subscribe to our email newsletter
Lupin’s divalproex sodium delayed-release tablets are the AB-rated generic equivalent of Abbott Laboratories’s Depakote tablets, indicated for the treatment of certain types of seizures and convulsions. It may be prescribed alone or with other epilepsy medications.
The delayed-release tablets are also used to control the manic episodes that occur in bipolar disorder.